Results 201 to 210 of about 39,918 (251)

Influence of apixaban on commonly used coagulation assays: results from the Belgian national External Quality Assessment Scheme

, 2017
Marjan Van Blerk, Els Bailleul, Bernard Châtelain, Anne Demulder, Katrien Devreese, Jonathan Douxfils, Marc Jacquemin, Kristin Jochmans, François Mullier, William Wijns, Bernard China, Kris Vernelen, Mohamed Rida Soumali   +12 more
openalex   +2 more sources

Emphysematous Gastritis Secondary to Embolic Infarction: A Case Report. [PDF]

Cureus
Chung YC, Naqash N.
europepmc   +1 more source

Position statement of the Polish Society of Gastroenterology on the use of andexanet alfa in patients with gastrointestinal bleeding taking factor Xa inhibitors. [PDF]

Prz Gastroenterol
Adrych K, Daniluk J, Nowakowska-Duława E, Białek A, Rydzewska GM.   +4 more
europepmc   +1 more source

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION

, 2015
А. В. Рудакова, В. А. Парфенов   +1 more
openalex   +2 more sources

Apixaban-Induced Leukocytoclastic Vasculitis: An Uncommon Complication of a Common Anticoagulant. [PDF]

Cureus
Gill S, Verma A, Vorachitti M, Boddupalli D.   +3 more
europepmc   +1 more source

Research Misconduct: Dabigatran, Rivaroxaban, Apixaban, Edoxaban

, 2015
Jorge H Ramírez
openalex   +1 more source

Apixaban in renal insufficiency: successful navigation between the Scylla and Charybdis [PDF]

, 2017
Hindricks, Gerhard, Steffel, Jan
core  

Apixaban-Induced Cutaneous Small Vessel Vasculitis.

Indian J Dermatol
Relhan V, Agrawal I, Grover S.
europepmc   +1 more source

Dose-reduced apixaban for secondary prophylaxis in patients with severe obesity: a single center analysis. [PDF]

Blood Adv
Rapoport EA, Townsend NW, Farhat N, Patel P, Billett HH.   +4 more
europepmc   +1 more source

Clinical experience with apixaban in atrial fibrillation: implications of AVERROES

, 2011
Raffaele De Caterina
openalex   +2 more sources